RE:RE:Going concernLangosta, you have raised a valid point that has been in the minds of pretty much every investor who are risking their hard earned money, believing in the Scope and immense potential for PDT to treat multiple forms of a dreaded disease. The turnover of Management is certainly NOT normal, especially for a company that employs less than 25 people!! I guess, Theralase technologies is not a Normal company and hope that the current management can bring it to BTD and Fast Track. Both objectives are achievable in the short term. They have even forecast for commercial production in 2023. It is almost a certainity that TLT will receive immense attention from other Major Pharma companies who are also working on similar or a variant of the same PDT. Merger or aquisition is very much an option!!!. Perhaps the most desirable option?